Acute myeloid leukemia with mutated nucleophosmin (NPMc+ AML) forms a distinct AML subgroup 24 with better prognosis which can potentially be associated with immune response against the 25 mutated nucleophosmin (NPM). As the T-cell-mediated immunity involves antigen presentation on 26 HLA class I molecules, we hypothesized that individuals with suitable HLA type could be less prone to 27 develop NPMc+ AML. We compared HLA class I distribution in NPMc+ AML patient cohort (398 28 patients from 5 centers) with the HLA allele frequencies of the caucasian population and found HLA-29 A*02, B*07, B*40 and C*07 underrepresented in the NPMc+ AML group. Presence of B*07 or 30 C*07:01 antigen was associated with better survival in patients without concomitant FLT3 internal 31 tandem duplication. Candidate NPM-derived immunopeptides were found for B*40 and B*07 using 32 prediction software tools. Our findings suggest that a T-cell-mediated immune response could 33 actually explain better prognosis of NPMc+ patients and provide a rationale for attempts to explore 34 the importance of immunosuppressive mechanisms in this AML subgroup. 35 36
Introduction 37
In relation with several breakthrough concepts, such as the introduction of immune checkpoint 38 inhibitors or the construction of T-cells with chimeric antigen receptors, the role of the immune 39 system in prevention and treatment of leukemias is currently intensively studied. The curative 40 potential of hematopoietic cell transplantation indicates that the activity of the immune system is 41 important also in acute myeloid leukemia (AML). However, the immune response is often inhibited 42 by a number of different mechanisms and although they are explored primarily in solid malignancies, 43 at least some of them are relevant also for AML [1] [2] [3] . Antibodies against inhibitory receptors, such as 44 ipilimumab, nivolumab and pembrolizumab, are efficient in blocking selected immunosuppressive 45 processes and are tested in clinical trials also for leukemias. In vitro studies show that the immune 46 checkpoint inhibition significantly increases the potential of cytotoxic T-cells to lyse leukemia blasts [4, 5] . One of the remaining obstacles in the development of protocols for adoptive immunotherapy is 48 the absence of suitable antigens. In the case of AML, pan-leukemic markers such as WT1, PRAME or 49 Aurora kinase are usually considered [6] . C-terminal mutations in nucleophosmin are characteristic 50 for AML, they are found in about a third of AML patients and are relatively stable during the disease 51 course [7] . Patients with these mutations form a specific group with better prognosis which might be 52 associated with an immune response against the mutated NPM1 or against its interaction partners 53 [8, 9] .
54
To test the hypothesis that T-cell mediated immune response contributes to disease control in 55 patients with NPM1 mutation, we compared the distribution of HLA class I allelic groups between 56 patients with NPM1-mutated AML and the normal population and we searched for an impact of the 57 HLA-repertoire of the patient on survival outcomes.
58
59 Results
60
We have previously performed a single-center pilot analysis of HLA class I distribution in patients 61 with acute myeloid leukemia (AML, N = 63). The study indicated that the frequency of several HLA 62 allelic groups was lower in patients with nucleophosmin mutations (denoted as NPMc+ in association 63 with the cytoplasmic localization of the mutated protein) compared to the normal values as well as 64 to the frequency observed in AML patients with wild-type NPM1 [10] . In the present study, we 65 analyzed HLA distribution in a larger cohort (398 patients with NPM1 mutation from 5 centers). The 66 basic parameters of the merged cohort and of the relevant subcohorts are given in Table 1 .
67 
74
The incidence of the HLA allelic groups A´02, B´07, B´40 and C´07 were found to be significantly lower 75 in AML NPMc+ patients compared to the normal frequency obtained from 76 www.allelefrequencies.net for caucasian populations (Fig 1) . On the other hand, the frequency of 77 A´24 was higher in the AML NPMc+ group. 
82
We further searched for possible impact of the HLA type on patient survival using Cox proportional 83 hazard regression with the following risk factors: age, the presence of internal tandem duplication in 84 FLT3 gene (Flt3-ITD), expression of HLA-A´02, HLA-B´07, HLA-B´40 and HLA-C´07. As expected, Flt3-85 ITD and age were the most critical factors (with p<0.0001 and p=0.0003, respectively). The influence 86 of the individual HLA allelic groups did not reach statistical significance. The data are available in 87 Supplementary Information.
88
We then analyzed in detail the overall survival curves for patients with and without expression of 89 each individual HLA class I allelic group. These groups were further subdivided according to the 90 presence or absence of Flt3-ITD which is a strong negative prognostic factor for AML. Although the 91 curves were similar in the majority of cases (see an example for HLA-A´02 in Fig 2A) , we found some 92 differences. First, patients with B´07 expression had better survival than non-B´07 patients ( Fig 2B, 93 left). The difference was detected only for patients without Flt3-ITD ( Fig 2B, right) . The expression of 94 B´40 was associated with worse survival ( 
100
A complex picture was obtained for C´07 which seemed to be a positive prognostic factor in Flt3-ITD-101 negative group and a negative one in Flt3-ITD+ group (Fig 2D, right) . The allelic group C´07 includes a 102 number of individual alleles and the two predominant ones, C*07:01 and C*07:02, have comparable 103 incidence. The majority of HLA data in the merged cohort were obtained by serology, which is not 104 able to discriminate among individual alleles of a group. However, in one subcohort (Prague center, 105 N = 94), all typings have been performed by molecular methods and we thus could analyze 106 separately the influence of C*07:01 and C*07:02 in this subcohort (Fig 3) . C*07:01, but not C*07:02 107 expression was associated with better survival trend although the differences were not statistically 108 significant, probably due to the smaller number of patients ( Fig 3B,C) . The positive effect of C*07:01 109 expression was only seen in the Flt3-ITD-negative subgroup (Fig 3B, right) . Fig 2B) . On the other hand, changes associated with C*07:01 are independent of B*07.
129
The main results of the statistical analyses are summarized in Table 2. 130 Table 2 Summary of results from the merged cohort and from the Prague subcohort Cohort HLA class I frequency distribution Effect of HLA type on the survival Merged (N = 398) **decrease in HLA-A´02 (p = 0.009) *decrease in HLA-B´07 (p = 0.0407) ***decrease in HLA-B´40 (p = 0.0007) ***decrease in HLA-C´07 (p = 0.0001) better survival in HLA-B´07+ group, specifically in the absence of Flt3-ITD (p = 0.05) worse survival in HLA-B´40+ group, especially in the absence of Flt3-ITD (p = 0.1163) Prague (N = 94) ***decrease in HLA-B*07 (p = 0.0007) decrease in HLA-B*40 (p = 0.1536) decrease in HLA-C*07:01 (p = 0.0869) ***decrease in HLA-C*07:02 (p = 0.00005) patients, compared to the distribution in the normal population [10] . To validate our previous 172 findings, we analyzed a larger cohort of AML patients with nucleophosmin mutation (N = 398). The 173 decrease of B´07, B´40 and C´07 frequency was reproduced and was statistically significant, 174 confirming a role for HLA class I type in the disease evolution (Fig 1, Table 2 ). In comparison with the 175 pilot study (N = 63), we did not found differences in the frequency of HLA-B´18 and C´03 in the 176 validation cohort. In addition, the analysis of the larger cohort indicated a decrease in HLA-A´02 177 frequency, which was not detected in the first cohort (Fig 1) . HLA-A´02 is the preferred allelic group 178 for the design of antigen-specific immunotherapeutical protocols as it is expressed in about a half of 179 the Caucassian population. However, we did not observe HLA-A´02 depletion in the Prague 180 subcohort ( Fig 3A) and patients with HLA-A´02 had no survival advantage in the merged cohort ( Fig   181  2A) , as well as in the subcohorts from the individual centers. No suitable NPM-derived peptide 182 binding to A´02 was found using theoretical predictions involving IEDB total processing score.
183
Therefore, we believe that other HLA context should be prioritized in the search for potential target sequences although NPM-derived peptides with affinity to HLA-A´02 may also stimulate an immune 185 response. We found the most consistent depletion in HLA-B´40 (Fig 1, Fig 3A) and, accordingly, 186 promising NPM-derived peptides for this allelic group were predicted (Table 3) . However, HLA-B´40 is 187 not very frequent and the positive effect of the spontaneous immune response seems to be limited 188 to the pre-diagnostic phase of the disease as the overall survival of B´40-positive patients was not 189 better ( Fig 2C) .
190
The depletion of B´07 at diagnosis is less marked in the merged cohort (Fig 1) , but a positive effect of 191 HLA-B´07 expression was also noted at later phases ( Fig 2B) and candidate NPM-derived peptides 192 could also be found for this allelic group (Table 3 ). In the Prague subcohort, B´07 was much less 193 frequent at diagnosis ( Fig 3A) , but the subsequent course of the disease was not better in B´07-194 positive group (Fig 3C) . This situation is similar to that found for B´40 in the whole merged cohort 195 (Table 2) . To explain these findings, we propose the following model: an efficient immune response 
202
Interesting results were also obtained in the case of HLA-C´07 allelic group, which is as frequent as 203 HLA-A´02 and has thus the potential to be used for generation of antigen-specific immune response.
204
However, the interpretation is more complicated in this case, as this allelic group involves two alleles 205 with comparable incidence which seem to differ in their impact. The analysis of the Prague subcohort 206 indicates that C*07:01 is a positive prognostic factor for the overall survival ( Fig 3B) in the absence of 207 Flt3-ITD. Decreased incidence of C´07 at diagnosis is probably due more to the linkage of C*07:02 208 with B*07:02 than to an immune response against antigens bound to C´07. Nevertheless, in the 209 merged cohort the decrease in C´07 is larger than that of B´07 (Fig 1) and the frequency of C*07:01 is 211 Although the prediction tools may not always identify all relevant antigens, the lack of suitable NPM-212 derived peptides for certain alleles may indicate the fact that the immune response is not directed 213 against NPM, but rather against another protein which is affected by altered localization and/or 214 signaling of the mutated NPM. Similar scenario was described for the fusion kinase BCR-ABL, which is 215 probably not immunogenic in itself but its expression increases the immunogenicity of its 216 downstream targets [14, 15] .
217
In general, the influence of HLA type on the overall survival is more marked in patients without Flt3-218 ITD (Figs 2 and 3 ). This correlates with the fact that patients with NPM1 mutations have more 219 favorable prognosis only in the absence of concomitant recurrent mutations, and especially in the 220 absence of Flt3-ITD [16] . The negative impact of Flt3-ITD is thus usually stronger than the benefit of 221 the presumed immune response.
223 Conclusions 224
We have identified three distinct HLA types of NPMc+ AML patients which differ in the disease 225 incidence and evolution (Table 2) 
250
The basic parameters of the merged cohort and of the relevant subgroups are given in Table 1 . 
